Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7% – Here’s What Happened

Rapport Therapeutics (NASDAQ:RAPP) shot up 5.7% on Wednesday . The company traded as high as $20.16 and last traded at $20.16. 7,396 shares traded hands during trading, a decline of 95% from the average session volume of 152,312 shares. The stock had previously closed at $19.07.

Rapport Therapeutics Stock Up 3.6 %

The business’s fifty day moving average is $23.12.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently bought and sold shares of RAPP. TD Asset Management Inc bought a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $2,361,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics during the second quarter worth approximately $58,105,000. Sofinnova Investments Inc. bought a new stake in shares of Rapport Therapeutics during the second quarter worth $45,393,000. Davidson Kempner Capital Management LP acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at $229,000. Finally, ARCH Venture Management LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth about $86,730,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.